From the Lab to Bedside in Myasthenia Gravis: Henry Kaminski, MD

The chairman of the department of neurology at George Washington University discussed his presentation at MDA 2022 and the value of hearing patient perspective at the conference. [WATCH TIME: 2 minutes]

WATCH TIME: 2 minutes

"Over the coming decade, we certainly hope to have some concordance of those [patient-reported outcomes] and better measures to see how patients are doing. The only way we do that is with the patient voice."

As the author of more than 100 peer-reviewed articles and book chapters, Henry Kaminski, MD, has been intertwined with the neuromuscular community for quite some time. He currently serves as the Meta Amalia Neumann professor, and the chair of the Department of Neurology at the George Washington University School of Medicine & Health Sciences. His research, which has been funded by the National Institutes of Health since 1993, focuses on understanding the biology of the extraocular muscles and the pathogenesis of myasthenia gravis (MG).

The 2022 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, March 13-16, held in Nashville, Tennessee, featured several notable presentations and sessions, one of which was chaired by Kaminski. Titled, "Lab to Life: MG," the session featured other experts including Petra Duda, MD, PhD; Sara M. Jones, MD; and Linda Kusner, PhD, as well as patient perspective from Meridith O’Connor, MSW. The group covered the continuum of development in MG, from the early and translational science efforts to the newly approved therapies that have become available in recent years.

Kaminski caught up with NeurologyLive® at the conference to discuss this organized session and the conversations and topics that were covered in it, and shared his perspective on the critical value in having patient voices present during these events.

For more coverage of MDA 2022, click here.